Media and reagents (e.g., are not adequately controlled for quality prior to being used in the aseptic manufacturing process.
Inspection Record
Abeona Therapeutics Inc — FDA 483 Findings
Inspectors Ou Olivia MaThe inspectors who signed the published document.Inspector lookup
View the regulator's official source The source document is always the basis for judgement.
Findings
Disinfectant efficacy studies performed to support the disinfectants used in the facility and during the manufacturing processes are deficient.
The inefficient management of deviations by Quality Assurance resulted in delayed investigations for which risk assessments were inadequate and adversely impacted final decisions and actions.
The aseptic manufacturing process lacks sufficient controls to ensure sterility of the prademagene zamikeracel final product, specifically: a.
A record as of the US FDA document published on 2026-10-26. Check the agency's announcements for any later corrective action, and rely on the original text. Translation and classification are machine-made.